Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of AMG0001 (HGF cDNA plasmid) in Critical Limb Ischemia
2014-001129-34Phase 3Terminated
- Sponsor
- AnGes, Inc.
- Start
- Sep 2014
- Modality
- Gene Therapies, Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic limb-threatening ischemia (CLTI) comparing AMG0001 (beperminogene perplasmid) with Placebo (2 arms). Primary endpoint: Time to major amputation of the index leg or all-cause death. Started Sep 2014; status: terminated.
02
Drugs
beperminogene perplasmid
03
Conditions
chronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on 2014-001129-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001129-34.